Sign In
Regional Medical Lab
Test Directory


JAK2 Mutation (V617F) Analysis

Order Name JAK2 MUTAT
Test Number: 9100185
Revision Date 07/11/2017
Test Name Methodology LOINC Code
JAK2 Mutation (V617F) Analysis
Qualitative PCR  
Specimen Specimen Volume (min) Specimen Type Specimen Container Transport Environment
Preferred 6mL (4mL) Whole Blood EDTA (Lavender Top) Room Temperature
Instructions Do Not use EDTA that has been sampled by an instrument or shared with any other testing.

6mL(4mL) Peripheral Whole Blood in EDTA Lavender top tube. Please keep specimens at room temperature or refrigerated. Do Not Centrifuge.
Stability is 8 days room temperature and refrigerated.
Testing Schedule Dayshift- Friday 
Expected TAT 5-6 Days  
Clinical Use Myeloproliferative disorders (MPDs) are clonal hematopoietic stem cell malignancies characterized by excessive production of blood cells by hematopoietic precursors. In addition to thrombotic and hemorrhagic complications, leukemic transformation can occur. The main members of MPD are Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Idiopathic Myelofibrosis (MF). The molecular pathogenesis of most MPDs is unknown. This V617F mutation leads to constituitive tyrosine phosphorylation activity that promotes cytokine activity and induces erythrocytosis. The V617F mutation in JAK2 is a dominant gain-of function mutation that contributes to the expansion of the myeloproliferative disorder clone. 
Notes Please Click here for Molecular Pre-Authorization information.
CPT Code(s) 81270
Lab Section Molecular Diagnostic